TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16799345

Group type: EXPERIMENTAL
Intervention: Intravenous anesthesia with propofol
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Inhalational anesthesia with isoflurane
Number of subjects: 29

Group type: COMPARATOR
Intervention: Both anesthetic techniques (propofol and isoflurane)
Number of subjects: 29
Study: 15259288

Group type: EXPERIMENTAL
Intervention: Conjugated estrogen plus medroxyprogesterone acetate (CE/MPA 0.625 mg/5 mg)
Number of subjects: 249

Group type: COMPARATOR
Intervention: 17beta‐estradiol plus norethisterone acetate (E2/NETA 2 mg/1 mg)
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Both CE/MPA and E2/NETA
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: CE/MPA 0.625 mg/5 mg
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: History of premenstrual syndrome (PMS)
Number of subjects: 249
Study: 11334726

Group type: COMPARATOR
Intervention: Oxaliplatin 85 mg/m(2) every 2 weeks
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Oxaliplatin combined with 5-FU 425 mg/m(2)/day and FA 20 mg/m(2)/dayx5 days every 4 weeks
Number of subjects: 73
Study: 9234925

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide 600 mg/m2 plus carboplatin 350 mg/m2
Number of subjects: 173

Group type: COMPARATOR
Intervention: Cyclophosphamide 1000 mg/m2 plus cisplatin 80 mg/m2
Number of subjects: 173
Study: 8438781

Group type: EXPERIMENTAL
Intervention: Nine meals per day
Number of subjects: 19

Group type: COMPARATOR
Intervention: Three meals per day
Number of subjects: 19
Study: 2445151

Group type: EXPERIMENTAL
Intervention: 2.5 mg nickel (nickel sulphate)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: 1 mg cobalt (cobalt sulphate)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 146

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 146
Study: 30993587

Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin (BV) at doses of 1.8 or 2.4 mg/kg once every three weeks
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin (BV)
Number of subjects: 63
Study: 28042070

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (FEC100→taxane) ± bevacizumab
Number of subjects: 84
Study: 25867783

Group type: EXPERIMENTAL
Intervention: Daily smartphone self-monitoring (n = 34)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Biweekly Web-survey only (n = 16)
Number of subjects: 50
Study: 23713407

Group type: EXPERIMENTAL
Intervention: Slow-release triamcinolone and lidocain injection
Number of subjects: 36

Group type: COMPARATOR
Intervention: Saline and lidocain injection
Number of subjects: 36
Study: 21475252

Group type: EXPERIMENTAL
Intervention: LDAC + ATO (0.25 mg/kg on days 1-5, 9, and 11 for at least four courses every 4 to 6 weeks)
Number of subjects: 166

Group type: COMPARATOR
Intervention: LDAC (20 mg b.d. for 10 days)
Number of subjects: 166
Study: 18641209

Group type: EXPERIMENTAL
Intervention: Combined treatment (100 mg L-theanine + 50 mg caffeine)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Caffeine alone (50 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: L-theanine alone (100 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16947448

Group type: EXPERIMENTAL
Intervention: Walking barefoot
Number of subjects: 75

Group type: COMPARATOR
Intervention: Everyday walking shoes
Number of subjects: 75
Study: 12915959

Group type: EXPERIMENTAL
Intervention: High calcium skimmed milk (50 g daily, containing 1200 mg calcium)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (usual diet)
Number of subjects: 200
Study: 10632100

Group type: EXPERIMENTAL
Intervention: Dichlorphenamide (DCP)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study: 8731105

Group type: EXPERIMENTAL
Intervention: Correction of acidosis (bicarbonate)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Acidosis (acid)
Number of subjects: 7
Study: 1474173

Group type: EXPERIMENTAL
Intervention: dimenhydrinate, 100 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: meclizine, 50 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: dimenhydrinate
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: meclizine
Number of subjects: 24
Study: 6386032

Group type: EXPERIMENTAL
Intervention: Superficial radiotherapy as an adjunct to topical therapy
Number of subjects: 15

Group type: COMPARATOR
Intervention: Simulated therapy (control)
Number of subjects: 15
Study: 31064805

Group type: EXPERIMENTAL
Intervention: PAL training delivered to teachers over two after-school sessions.
Number of subjects: 321
Study: 29448833

Group type: EXPERIMENTAL
Intervention: luseogliflozin 2.5 mg
Number of subjects: 233

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 233
Study: 25532501

Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF)
Number of subjects: 641
Study: 23886432

Group type: EXPERIMENTAL
Intervention: HDM-SLIT
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 22089958

Group type: EXPERIMENTAL
Intervention: Vibrotactile neurofeedback training (15 min daily for 2 weeks)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 105
Study: 20128284

Group type: EXPERIMENTAL
Intervention: Intravenous dexamethasone for 4 days along with anti-inflammatory drug
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo along with anti-inflammatory drug
Number of subjects: 60
Study: 17729433

Group type: EXPERIMENTAL
Intervention: Periinterventional prophylactic antibiosis (Unacid 3 g or Ciprobay 100 mg for penicillin allergy)
Number of subjects: 164

Group type: COMPARATOR
Intervention: No prophylactic antibiosis
Number of subjects: 164
Study: 15042123

Group type: EXPERIMENTAL
Intervention: cellobiose‐[13C]ureide
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: glucose‐[13C]ureide
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: cellobiose‐[13C]ureide with predosing of unlabelled cellobiose ureide
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: glucose‐[13C]ureide with predosing of unlabelled glucose ureide
Number of subjects: 8
Study: 11729368

Group type: EXPERIMENTAL
Intervention: PEG-hirudin low dose (0.1 mg/kg bolus, 0.01 mg/kg/h infusion)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: PEG-hirudin intermediate dose (0.15 mg/kg and 0.015 mg/kg/h)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: PEG-hirudin high dose (0.2 mg/kg and 0.02 mg/kg/h)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Heparin (control group)
Number of subjects: 30
Study: 9725759

Group type: EXPERIMENTAL
Intervention: Nicotine
Number of subjects: 0
Study: 9376032

Group type: EXPERIMENTAL
Intervention: CO2 laser treatment
Number of subjects: 44

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 44
Study: 1837646

Group type: EXPERIMENTAL
Intervention: Recombinant hepatitis B vaccine (GenHevac B Pasteur) 20 micrograms administered at birth, 1 month, 2 months, and booster at 12 months; in combination with 100 IU HBIg for high risk group.
Number of subjects: 37

Group type: COMPARATOR
Intervention: Recombinant hepatitis B vaccine (GenHevac B Pasteur) 20 micrograms administered at birth, 1 month, 2 months, and booster at 12 months; alone for low risk group.
Number of subjects: 37
Study: 6751067

Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 30859691

Group type: EXPERIMENTAL
Intervention: Anodized titanium oxide abutments
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control machined titanium abutments
Number of subjects: 35
Study: 29410046

Group type: EXPERIMENTAL
Intervention: Dexamethasone (DEX) treatment
Number of subjects: 104
Study: 26838691

Group type: EXPERIMENTAL
Intervention: Left atrial appendage closure (LAAC) with the Watchman device
Number of subjects: 0
Study: 24393277

Group type: EXPERIMENTAL
Intervention: Lactobacillus paracasei NCC2461 for 4 weeks
Number of subjects: 31

Group type: COMPARATOR
Intervention: Blend of Lactobacillus acidophilus ATCC SD5221 and Bifidobacterium lactis ATCC SD5219 for 4 weeks
Number of subjects: 31
Study: 23104251

Group type: EXPERIMENTAL
Intervention: Baseline levels of CXCL16
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Baseline levels of PTX3
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Baseline levels of von Willebrand factor (vWF)
Number of subjects: 248
Study: 20098960

Group type: EXPERIMENTAL
Intervention: Experimental stannous‐containing sodium fluoride dentifrice
Number of subjects: 31

Group type: COMPARATOR
Intervention: Regular sodium fluoride negative control
Number of subjects: 31
Study: 18797301

Group type: EXPERIMENTAL
Intervention: Semantically related prime
Number of subjects: 0

Group type: COMPARATOR
Intervention: Semantically unrelated prime
Number of subjects: 0
Study: 15921805

Group type: EXPERIMENTAL
Intervention: Nebivolol
Number of subjects: 260

Group type: COMPARATOR
Intervention: Control (Placebo)
Number of subjects: 260
Study: 11912265

Group type: EXPERIMENTAL
Intervention: Hemodiafiltration (HDF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard Hemodialysis (HD)
Number of subjects: 0
Study: 9564124

Group type: EXPERIMENTAL
Intervention: Information intervention
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Relaxation intervention
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 61
Study: 7877340

Group type: EXPERIMENTAL
Intervention: Pressure plaster of Semen Impatientis on otoacupoints
Number of subjects: 295

Group type: COMPARATOR
Intervention: Control group (similar cases)
Number of subjects: 295
Study: 3063335

Group type: EXPERIMENTAL
Intervention: High-dose intravenous alizapride (3.5 mg/kg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: High-dose intravenous metoclopramide (1 mg/kg)
Number of subjects: 40
Study: 27599818

Group type: EXPERIMENTAL
Intervention: Educational program and six case conferences
Number of subjects: 140
Study: 27760143

Group type: EXPERIMENTAL
Intervention: Irradiated (150 ± 10 cGy) Pv-infected Anopheles mosquitoes (RAS)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Non-irradiated non-infected mosquitoes (Ctl)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Non-irradiated Pv-infected mosquitoes (Fy-)
Number of subjects: 28
Study: 24944332

Group type: EXPERIMENTAL
Intervention: Dual-release hydrocortisone (DR-HC) 20-40 mg once daily
Number of subjects: 64

Group type: COMPARATOR
Intervention: Thrice-daily hydrocortisone 20-40 mg divided into three daily doses
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Dual-release hydrocortisone (DR-HC)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Thrice-daily hydrocortisone
Number of subjects: 64
Study: 22709705

Group type: EXPERIMENTAL
Intervention: Intervention group (MyPyramid Menu Planner for Moms)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Minimal Care group
Number of subjects: 27
Study: 20816297

Group type: EXPERIMENTAL
Intervention: Modified fluoride toothpaste technique (MFTT)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Routine oral hygiene instructions with fluoride toothpaste
Number of subjects: 100
Study: 18472682

Group type: EXPERIMENTAL
Intervention: Low blood pressure goal (mean arterial pressure [MAP] of 92 mm/Hg or lower)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual blood pressure goal (MAP of 102-107)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable (randomized drug assignments)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Not applicable (baseline characteristics)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Not applicable (income status)
Number of subjects: 0
Study: 16167793

Group type: EXPERIMENTAL
Intervention: Fentanyl 21 microg x hr(‐1) with ropivacaine
Number of subjects: 58

Group type: COMPARATOR
Intervention: Fentanyl 11 microg x hr(‐1) with ropivacaine
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 58
Study: 12873958

Group type: EXPERIMENTAL
Intervention: Local anesthetic solution with epinephrine (Group E)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Local anesthetic solution without epinephrine (Group P)
Number of subjects: 110
Study: 10584882

Group type: EXPERIMENTAL
Intervention: Continuous hyperfractionated accelerated radiotherapy (CHART)
Number of subjects: 615

Group type: COMPARATOR
Intervention: Conventional radiotherapy
Number of subjects: 615
Study: 8917260

Group type: EXPERIMENTAL
Intervention: Resistance exercise training for 6 months (lumbar extension exercise performed 1 day/week and variable resistance exercises performed 2 days/week)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (no resistance exercise)
Number of subjects: 16
Study: 1615615

Group type: EXPERIMENTAL
Intervention: 1 g of cefadroxil once a day for three days
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: 100 mg of nitrofurantoin three times a day for three days
Number of subjects: 362

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 362
Study: 6228746

Group type: EXPERIMENTAL
Intervention: Gamma-vinyl GABA, 2 g/day
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 31780017

Group type: EXPERIMENTAL
Intervention: N. sativa 5% gel
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 29466116

Group type: EXPERIMENTAL
Intervention: Low-Level Laser Therapy (LLLT)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo LLLT
Number of subjects: 15
Study: 27436275

Group type: COMPARATOR
Intervention: Exenatide QW 2 mg (self-administered)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Exenatide QMS 5 mg (caregiver-administered)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Exenatide QMS 8 mg (caregiver-administered)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Exenatide QMS 11 mg (caregiver-administered)
Number of subjects: 121
Study: 24831438

Group type: EXPERIMENTAL
Intervention: Modified oral food challenge with doses of roasted peanuts ranging from 3 to 4500 mg of peanut protein
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Modified oral food challenge
Number of subjects: 63
Study: 22383993

Group type: EXPERIMENTAL
Intervention: Daclizumab (anti-IL-2Rα monoclonal antibody), given during lymphodepleting temozolomide (TMZ) treatment
Number of subjects: 6

Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Daclizumab
Number of subjects: 6
Study: 20920802

Group type: EXPERIMENTAL
Intervention: Acupressure at Sanyinjiao point
Number of subjects: 86

Group type: COMPARATOR
Intervention: Sham acupressure
Number of subjects: 86
Study: 17397924

Group type: EXPERIMENTAL
Intervention: Viscocanalostomy with phacoemulsification
Number of subjects: 40

Group type: COMPARATOR
Intervention: Trabeculectomy with mitomycin C and phacoemulsification
Number of subjects: 40
Study: 16143126

Group type: EXPERIMENTAL
Intervention: Selenomethionine 200 microg daily
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg twice daily
Number of subjects: 267

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 267
Study: 11880968

Group type: EXPERIMENTAL
Intervention: Indinavir-containing regimen (with zidovudine and lamivudine)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Nelfinavir-containing regimen (with zidovudine and lamivudine)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Combination therapy (indinavir or nelfinavir with zidovudine and lamivudine)
Number of subjects: 32
Study: 10217083

Group type: EXPERIMENTAL
Intervention: Home-based peer counselling with six visits
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Home-based peer counselling with three visits
Number of subjects: 130

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Intervention groups (six and three visits combined)
Number of subjects: 130
Study: 7477806

Group type: COMPARATOR
Intervention: Psychopharmacological treatment (details not provided)
Number of subjects: 137
Study: 2080934

Group type: EXPERIMENTAL
Intervention: Calcitonin nasal spray (200 IU intranasal daily for one year)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 36
Study: 531075

Group type: EXPERIMENTAL
Intervention: 5 mg oral methadone
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: 10 mg oral methadone
Number of subjects: 3

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study: 31225894

Group type: EXPERIMENTAL
Intervention: High trust
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Improved or stable high trust
Number of subjects: 165
Study: 28521837

Group type: EXPERIMENTAL
Intervention: Implanon
Number of subjects: 524

Group type: EXPERIMENTAL
Intervention: Health extension workers as information source
Number of subjects: 524

Group type: EXPERIMENTAL
Intervention: Good knowledge of Implanon
Number of subjects: 524

Group type: EXPERIMENTAL
Intervention: Supportive attitudes towards Implanon use
Number of subjects: 524

Group type: EXPERIMENTAL
Intervention: Factors influencing Implanon use
Number of subjects: 524
Study: 24973230

Group type: EXPERIMENTAL
Intervention: EEG theta/beta ratio (tbr)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: EEG beta-1 power
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: EEG beta-1 power over Broca's area
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: EEG theta/beta ratio (tbr) over Broca's area
Number of subjects: 86
Study: 22573338

Group type: EXPERIMENTAL
Intervention: SCT-based email intervention targeting physical activity, 12 weeks duration
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control group (no email messages, no e-counselor access)
Number of subjects: 74
Study: 21455059

Group type: EXPERIMENTAL
Intervention: MP4OX
Number of subjects: 367

Group type: COMPARATOR
Intervention: Hydroxyethyl starch 130/0.4
Number of subjects: 367
Study: 19335655

Group type: EXPERIMENTAL
Intervention: Computerized prevention program (n = 611, eight schools)
Number of subjects: 1466

Group type: COMPARATOR
Intervention: Usual classes (n = 855, eight schools)
Number of subjects: 1466

Group type: EXPERIMENTAL
Intervention: Computerized prevention program (for females)
Number of subjects: 1466

Group type: EXPERIMENTAL
Intervention: Computerized prevention program (for males)
Number of subjects: 1466
Study: 16757527

Group type: EXPERIMENTAL
Intervention: rhGH (6 mg daily injection for 3 months)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo (self-administered for 3 months)
Number of subjects: 27
Study: 15313211

Group type: EXPERIMENTAL
Intervention: Mitochondrial enzymatic activity study
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Mitochondrial DNA amplification using PCR
Number of subjects: 200
Study: 11522739

Group type: EXPERIMENTAL
Intervention: Cooked green banana (250 g/L)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Pectin (4 g/kg)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Rice-diet alone (control)
Number of subjects: 62
Study: 9322269

Group type: EXPERIMENTAL
Intervention: Temazepam 20 mg
Number of subjects: 0
Study: 8280545

Group type: EXPERIMENTAL
Intervention: Oral bromfenac 10 mg
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Oral bromfenac 25 mg
Number of subjects: 91

Group type: COMPARATOR
Intervention: Sublingual buprenorphine 0.2 mg
Number of subjects: 91

Group type: COMPARATOR
Intervention: Sublingual buprenorphine 0.4 mg
Number of subjects: 91
Study: 3103972

Group type: EXPERIMENTAL
Intervention: High glucose intake
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low glucose intake
Number of subjects: 0
Study: 29377474

Group type: EXPERIMENTAL
Intervention: Eculizumab (single dose prior to transplantation)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control (no eculizumab)
Number of subjects: 57
Study: 27543529

Group type: EXPERIMENTAL
Intervention: Predictive models using clinical characteristics and central venous blood gas values
Number of subjects: 590

Group type: EXPERIMENTAL
Intervention: Thresholds of predicted variables from the derivation set
Number of subjects: 590
Study: 25597173

Group type: EXPERIMENTAL
Intervention: Vitamin D (200 IU/d) and calcium (600 mg/d)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Vitamin E (100 mg) and vitamin C (100 mg)
Number of subjects: 86
Study: 22918825

Group type: EXPERIMENTAL
Intervention: Radiofrequency kyphoplasty (RFK)
Number of subjects: 181

Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 181
Study: 20439627

Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogen (CEE; 0.625 mg/d)
Number of subjects: 10739

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10739
Study: 18762911

Group type: EXPERIMENTAL
Intervention: Bioabsorbable screw fixation
Number of subjects: 62

Group type: COMPARATOR
Intervention: Metal screw fixation
Number of subjects: 62
Study: 16881241

Group type: EXPERIMENTAL
Intervention: Supported employment program
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Other programs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Passive job seekers
Number of subjects: 0
Study: 12814319

Group type: EXPERIMENTAL
Intervention: 2 IMZ implants placed in a single-stage procedure
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 2 IMZ implants placed in the traditional 2-stage procedure
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 2 ITI implants (single-stage procedure)
Number of subjects: 60
Study: 11010659

Group type: EXPERIMENTAL
Intervention: Profound condition (writing about bereavement experience)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Trivial condition (writing about innocuous topics)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Both conditions (Profound and Trivial)
Number of subjects: 64
Study: 8794418

Group type: EXPERIMENTAL
Intervention: Replens (non-hormonal moisturizing vaginal gel) applied three times a week for 12 weeks
Number of subjects: 39

Group type: COMPARATOR
Intervention: Dienoestrol (oestrogenic vaginal cream) administered daily for the first 2 weeks and then three times a week
Number of subjects: 39
Study: 1638171

Group type: EXPERIMENTAL
Intervention: L-deprenyl (5 mg twice a day for 60 days)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 6465938

Group type: EXPERIMENTAL
Intervention: Nebulized salbutamol
Number of subjects: 46

Group type: COMPARATOR
Intervention: Injected adrenaline
Number of subjects: 46
Study: 31076136

Group type: EXPERIMENTAL
Intervention: Neurology Hat Game
Number of subjects: 121
Study: 28166806

Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (BoNT‐A) injections in the calf muscles
Number of subjects: 96

Group type: COMPARATOR
Intervention: 0.9% saline injections in the calf muscles (placebo)
Number of subjects: 96